Nuvation Bio Inc - Ordinary Shares - Class A Stock News

Nuvation Bio is demonstrating strong early commercial success with Ibtrozi, its newly FDA-approved therapy for ROS1-positive non-small cell lung cancer. NUVB reported 204 new patients for Ibtrozi in the latest quarter, supporting a robust revenue trajectory and validating the product's market potential. A conservative revenue projection supports NUVB's current market cap. The value of ex-US mar...

Nuvation Bio Inc. ( NUVB ) Q3 2025 Earnings Call November 3, 2025 4:30 PM EST Company Participants Robert DeVita David Hung - Founder, President, CEO & Chairman Colleen Sjogren - Chief Commercial Officer Philippe Sauvage - CFO & Principal Financial Officer Conference Call Participants Kaveri Pohlman - Clear Street LLC Farzin Haque - Jefferies LLC, Research Division Soumit Roy - JonesTrading Ins...

NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today reported financial results for the third quarter ended September 30, 2025, and provided a business update. “We are thrilled that 204 new patients have received IBTROZI during our first full quarter as a commercial-stage company,” sai...

Gary Hattersley, chief scientific officer at Nuvation Bio (NUVB +1.36%), exercised and immediately sold 100,000 shares of Class A common stock in an open-market derivative transaction on October 27, according to an SEC Form 4 filing.

NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that David Hung, M.D., Founder, President, and Chief Executive Officer of Nuvation Bio, and Philippe Sauvage, Chief Financial Officer of Nuvation Bio, will participate in three upcoming investor conferences, including fires...

NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced enrollment of the first patient into part 2 of G203 (NCT05303519), a global, randomized study evaluating the efficacy and safety of safusidenib versus placebo for the maintenance treatment of patients with high-grade IDH1-m...

NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced it will host a conference call and webcast on Monday, November 3, 2025, at 4:30 p.m. ET to discuss its financial results and business updates for the third quarter of 2025. Investors and the general public are invited to li...

Shares of Nuvation Bio (NUVB 14.13%) were skyrocketing 15.7% higher as of 11:20 a.m. ET on Tuesday.